Delving into the Latest Updates on Cixutumumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Cixutumumab (USAN)

+ [5]

Target

IGF-1R

Mechanism

IGF-1R antagonists(Insulin-like growth factor I receptor antagonists)

Therapeutic Areas

NeoplasmsDigestive System DisordersOther Diseases

Active Indication

Adenocarcinoma of EsophagusGastrooesophageal junction cancerMetastatic Esophageal Carcinoma+ [3]

Inactive Indication

Adenocarcinoma of prostateAdipose Tissue NeoplasmsAdrenocortical Carcinoma+ [75]

Originator Organization

Eli Lilly & Co.

Active Organization

National Cancer Institute

Inactive Organization

Eli Lilly & Co.

Genentech, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 193839L

Source: *****

Sequence Code 201122H

Source: *****

This phase II trial studies how well cixutumumab and temsirolimus work in treating patients with recurrent or refractory sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cixutumumab and temsirolimus together may kill more tumor cells.

Start Date18 Jun 2012

Sponsor / Collaborator

National Cancer Institute

NCT00957853 / CompletedPhase 2IIT

An Exploratory Study to Assess the Modulation of Biomarkers in Patients With Squamous Cell Carcinomas of the Head and Neck Randomized to Receive Preoperative Treatment With Cetuximab and/or IMC-A12, an Anti-insulin-like Growth Factor-1 Receptor Monoclonal Antibody

The goal of this clinical research study is to give cetuximab and/or IMC-A12 before surgery for squamous cell carcinoma of the head and neck, in order to learn if these study drugs may cause changes in biomarkers. Biomarkers are chemical "markers" in the blood and/or tissue that may be related to a reaction to study treatment.
The safety of the study treatments will also be studied.

Start Date17 Oct 2011

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

NCT01413191 / CompletedPhase 2IIT

Phase II Study of IMC-A12 in Metastatic Uveal Melanoma

This phase II trial studies how well giving cixutumumab works in treating patients with metastatic melanoma of the eye. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

Start Date01 Aug 2011

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Cixutumumab

Login to view more data

100 Translational Medicine associated with Cixutumumab

Login to view more data

100 Patents (Medical) associated with Cixutumumab

Login to view more data

201

Literatures (Medical) associated with Cixutumumab

13 Nov 2024·Journal of Agricultural and Food Chemistry

Design, Synthesis, and Biological Activity Studies of Myricetin Derivatives Containing a Diisopropanolamine Structure

Article

Author: Zou, Hongqian ; Qiu, Yujiao ; An, Youshan ; Xue, Wei ; Tian, Jiao ; Deng, Tianyu ; Zhou, Qing

A series of myricetin derivatives containing diisopropanolamine were designed and synthesized. The in vitro inhibitory effects of the target compounds on 9 fungal pathogens and 3 bacterial pathogens were also evaluated. A12 had the best inhibitory effect against Xanthomonas oryzae pv. oryzae (Xoo), with an EC₅₀ value of 4.9 μg/mL, which was better than zinc-thiazole (ZT: EC₅₀ = 7.3 μg/mL) and thiodiazole-copper (TC: EC₅₀ = 65.5 μg/mL); A25 had the best inhibitory effect against Phomopsis sp. (Ps), with an EC₅₀ value of 17.2 μg/mL, which was better than azoxystrobin (Az: EC₅₀ = 22.3 μg/mL). In vivo inhibition tests were performed on kiwifruit for A25 and rice leaves for A12. At 200 μg/mL, the curative activity of A12 against rice leaf blight was 40.7%, which was better than that of ZT (37.2%) and TC (32.9%), and the protective activity of A12 was 44.8%, which was better than that of ZT (39.5%) and TC (34.6%). The curative activity of A25 against kiwi soft rot disease was 70.1%, which was better than that of Az (62.8%). Preliminary elucidation of the possible mechanisms of action was carried out by experiments on fluorescence microscopy, scanning electron microscopy, formation of biofilms, density functional theory calculations, and so on.

02 Sep 2024·Journal of Applied Microbiology

Enhanced bioremediation of soils contaminated with nicosulfuron using the bacterial complex A12

Article

Author: Wang, Siya ; Yang, Bingbing ; Zhang, Hao ; Dong, Meiqi ; Xiao, Yufeng ; Wu, Xian

AbstractAimsTo construct an efficient bacterial complex to degrade nicosulfuron and clarify its degradative characteristics, promote the growth of maize (Zea mays), and provide a theoretical foundation for the efficient remediation of soil contaminated with nicosulfuron.Methods and resultsBiocompatibility was determined by the filter paper sheet method by mixing Serratia marcescens A1 and Bacillus cereus A2 in a 1:1 ratio, yielding A12. The optimum culture conditions for the bacterial composite were obtained based on a three-factor, three-level analysis using response surface methodology, with 29.25 g l−1 for maltodextrin, 10.04 g l−1 for yeast extract, and 19.93 g l−1 for NaCl, which resulted in 92.42% degradation at 4 d. The degradation characteristics of A12 were clarified as follows: temperature 30°C, pH 7, initial concentration of nicosulfuron 20 mg l−1, and 4% inoculum. The ability to promote growth was determined by measuring the ratio of the lysosphere diameter (D) to the colony diameter (d), and the ability of the complex A12 to promote growth was higher than that of the two single strains.ConclusionsNicosulfuron degradation in sterilized and unsterilized soils reached 85.4% and 91.2% within 28 d, respectively. The ability of the strains to colonize the soil was determined by extraction of total soil DNA, primer design, and gel electrophoresis. The bioremediation effect of A12 was confirmed by the maximum recovery of fresh weight (124.35%) of nicosulfuron-sensitive crop plants and the significant recovery of soil enzyme activities, as measured by the physiological indices in the sensitive plants.

01 May 2024·Surgery

An engineered poly(A) tail attenuates gut ischemia/reperfusion-induced acute lung injury

Article

Author: Wang, Ping ; Jha, Alok ; Aziz, Monowar ; Murao, Atsushi

BACKGROUNDGut ischemia/reperfusion causes the release of damage-associated molecular patterns, leading to acute lung injury and high mortality. Cold-inducible ribonucleic acid-binding protein is a ribonucleic acid chaperon that binds the polyadenylation tail of messenger ribonucleic acid intracellularly. Upon cell stress, cold-inducible ribonucleic acid-binding protein is released, and extracellular cold-inducible ribonucleic acid-binding protein acts as a damage-associated molecular pattern, worsening inflammation. To inhibit extracellular cold-inducible ribonucleic acid-binding protein, we have recently developed an engineered polyadenylation tail named A₁₂. Here, we sought to investigate the therapeutic potential of A₁₂ in gut ischemia/reperfusion-induced acute lung injury.METHODSMale C57BL6/J mice underwent superior mesenteric artery occlusion and were treated with intraperitoneal A₁₂ (0.5 nmol/g body weight) or vehicle at the time of reperfusion. Blood and lungs were collected 4 hours after gut ischemia/reperfusion. Systemic levels of extracellular cold-inducible ribonucleic acid-binding protein, interleukin-6, aspartate transaminase, alanine transaminase, and lactate dehydrogenase were determined. The pulmonary gene expression of cytokines (interleukin-6, interleukin-1β) and chemokines (macrophage-inflammatory protein-2, keratinocyte-derived chemokine) was also assessed. In addition, lung myeloperoxidase, injury score, and cell death were determined. Mice were monitored for 48 hours after gut ischemia/reperfusion for survival assessment.RESULTSGut ischemia/reperfusion significantly increased the serum extracellular cold-inducible ribonucleic acid-binding protein levels. A₁₂ treatment markedly reduced the elevated serum interleukin-6, alanine transaminase, aspartate transaminase, and lactate dehydrogenase by 53%, 23%, 23%, and 24%, respectively, in gut ischemia/reperfusion mice. A₁₂ also significantly decreased cytokine and chemokine messenger ribonucleic acids and myeloperoxidase activity in the lungs of gut ischemia/reperfusion mice. Histological analysis revealed that A₁₂ attenuated tissue injury and cell death in the lungs of gut ischemia/reperfusion mice. Finally, administration of A₁₂ markedly improved the survival of gut ischemia/reperfusion mice.CONCLUSIONA₁₂, a novel extracellular cold-inducible ribonucleic acid-binding protein inhibitor, diminishes inflammation and mitigates acute lung injury when employed as a treatment during gut ischemia/reperfusion. Hence, the targeted approach toward extracellular cold-inducible ribonucleic acid-binding protein emerges as a promising therapeutic strategy for alleviating gut ischemia/reperfusion-induced acute lung injury.

100 Deals associated with Cixutumumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09328	Cixutumumab	-	DB12250

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peripheral Primitive Neuroectodermal Tumors	Phase 2	FR	Eli Lilly & Co.	01 Jul 2008
Peripheral Primitive Neuroectodermal Tumors	Phase 2	DE	Eli Lilly & Co.	01 Jul 2008
Peripheral Primitive Neuroectodermal Tumors	Phase 2	US	Eli Lilly & Co.	01 Jul 2008
Peripheral Primitive Neuroectodermal Tumors	Discovery	PL	Eli Lilly & Co.	01 Jul 2008
Peripheral Primitive Neuroectodermal Tumors	Discovery	NL	Eli Lilly & Co.	01 Jul 2008
Recurrent Squamous Cell Carcinoma of the Head and Neck	Discovery	US	Eli Lilly & Co.	01 Mar 2008
Secondary malignant neoplasm of pancreas	Discovery	US	National Cancer Institute	01 Mar 2008
Adenocarcinoma of prostate	Discovery	US	Eli Lilly & Co.	01 Aug 2007
Metastatic Prostate Carcinoma	Discovery	US	Eli Lilly & Co.	01 Aug 2007
Metastatic Colorectal Carcinoma	Discovery	US	Eli Lilly & Co.	01 Jun 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01142388 (Pubmed)	Phase 2	Metastatic Gastroesophageal Junction Adenocarcinoma Second line	87	Paclitaxel	(enmraarvpr) = gljghqiqlq jpubqpmjqp (jzgfolpcgo, 1.8 - 3.5) View more	Negative	27 Apr 2023
				Paclitaxel plus Cixutumumab	(enmraarvpr) = awtpfwagpx jpubqpmjqp (jzgfolpcgo, 2.0 - 3.5) View more
NCT01413191 (Pubmed \| Melanoma Res) Manual	Phase 2	Uveal Melanoma	18	imc-a12	(lfqjdkfvzm) = qalrwnbvzl qxwlnjrsgl (xtszyewief ) View more	Negative	01 Dec 2020
NCT01026623 (Pubmed \| Clin Genitourin Cancer) Manual	Phase 1	Metastatic castration-resistant prostate cancer	16	cixutumumab+Temsirolimus (cohort 1)	(muwipwfrmk) = The most common adverse events included hyperglycemia (100%; 31% grade 3), oral mucositis (63%; 19% grade 3), and diarrhea (44%; 0 grade 3). Low-grade pneumonitis occurred in 7 of 11 patients (44%; 0 grade 3). tjwkdguujc (eehowzaawj ) View more	Negative	01 Jun 2020
				cixutumumab+Temsirolimus (cohort -1)
NCT00957853 (CTgov)	Phase 2	Squamous Cell Carcinoma of Head and Neck	16	Cetuximab (Cetuximab)	rlvgcsimlv(kxtbgvyylm) = cqkqgislrp jagjxoldai (avmbzuuyqz, tmllbuthjx - rvstdjgpqk) View more	-	19 Mar 2020
				IMC-A12 (IMC-A12)	rlvgcsimlv(kxtbgvyylm) = bwtqzjrvvd jagjxoldai (avmbzuuyqz, hqmomdlnrg - djfddanbju) View more
NCT01120236 (SWOG S0925, ASCO_GU2020)	Phase 2	Castration-Resistant Prostatic Cancer	210	Androgen deprivation + cixutumumab	(pdjarmsntx): HR = 1.01 (95% CI, 0.7 - 1.45), P-Value = 0.97 View more	Negative	19 Feb 2020
				Androgen deprivation
NCT01263782 (CTgov)	Phase 2	Advanced Lung Non-Small Cell Carcinoma	64	Carboplatin+Pemetrexed (Carboplatin + Pemetrexed x 4 Cycles Followed by Maintenance Pe)	kjgexxfxhv(kxzvotunao) = ufxhtycdrk ljltklbvul (xxyrtgbvnp, xzrynjjwhb - qgyyfcinbl) View more	-	08 May 2019
				Carboplatin+Bevacizumab+Pemetrexed (Carboplatin + Pemetrexed + Bevacizumab Followed by Maintenance)	kjgexxfxhv(kxzvotunao) = izovsilraz ljltklbvul (xxyrtgbvnp, mzcewcfspy - qdcukpyszs) View more
NCT01007032 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm	21	Cixutumumab (Cixutumumab Cohort 1)	dojskzgjnx(wfzgyvsaot) = sdflaxabqv hzaldubhas (dmtrsgxjcd, xyvsqltcee - crqmionmyj) View more	-	27 Feb 2019
				Cixutumumab (Cixutumumab Cohort 2)	dojskzgjnx(wfzgyvsaot) = mwyepwhisp hzaldubhas (dmtrsgxjcd, xeupseciio - ruwtwlykek) View more
NCT00785538 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm	24	IMC-A12 (3 mg/kg)	gcljrphywz(xrcjipyzqv) = dwpakmnclh jmpjontwqw (qniusnshra, tjzenlvpqa - buakrdabuu) View more	-	22 Oct 2018
				IMC-A12 (6 mg/kg)	gcljrphywz(xrcjipyzqv) = ztmhbmkqyg jmpjontwqw (qniusnshra, nzeissbjpi - wwblrmqtbv) View more
NCT00520481 (CTgov)	Phase 2	Metastatic Prostate Carcinoma \| Adenocarcinoma of prostate	41	Cixutumumab (Cixutumumab 10 mg/kg)	iflfpnofwq(ipxuyracck) = icqnjmypqa gwmhpnvliw (egxkunfwrd, yqcjehgmsk - ulgcimasds) View more	-	19 Jul 2018
				Cixutumumab (Cixutumumab 20 mg/kg)	iflfpnofwq(ipxuyracck) = sodpaminvi gwmhpnvliw (egxkunfwrd, ftrraygwwu - fywujybczq) View more
NCT00668148 (CTgov)	Phase 2	Peripheral Primitive Neuroectodermal Tumors \| Leiomyosarcoma \| Rhabdomyosarcoma \| Synovial Sarcoma \| Advanced Sarcoma \| Adipose Tissue Neoplasms	113	IMC-A12 (cixutumumab) (Ewing's Sarcoma/PNET)	mgwskbstcd(ismunwgriv) = urqixlktmt xmektblqde (vaxbtvcgpj, sdypwvcwgh - dpcqtsssrr) View more	-	17 Jul 2018
				IMC-A12 (cixutumumab) (Rhabdomyosarcoma)	mgwskbstcd(ismunwgriv) = iaccqfxmhg xmektblqde (vaxbtvcgpj, xkmsjfksph - kkuhvuhaba) View more